Clinical Trial Update: Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating recombinant human adenovirus type 5 in advanced hepatocellular carcinoma patients with stable disease after sorafenib.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Recombinant human adenovirus type 5 (Adenovirus type 5 vector)

Snippet

Sponsor: First Affiliated Hospital Xi'an Jiaotong University | Conditions: Hepatocellular Carcinoma | Phase 4 | Status: UNKNOWN